Skip to content
drillr.ai
Sign up

06887.HK

Sunshine Lake Pharma Co., Ltd.

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

HKD 39.90
−0.75%
Ask drillr

  • Oct 8, 2026, 08:47 UTC

    China approved Sunshine Lake Pharma Co., Ltd.’s independently developed insulin degludec/aspart for treating adults with type 2 diabetes.

    Source:

  • Sep 30, 2026, 00:30 UTC

    Sunshine Lake Pharma (Dongguan HEC) repurchased 120,000 of its own shares on September 29 at HK$42.28–42.36 per share for about HK$5.079 million.

    Source:

  • Sep 29, 2026, 00:38 UTC

    Sunshine Lake Pharma repurchased 16,000 of its own shares on September 28, 2026 at prices between HK$39.4 and HK$40 per share for about HK$635,500.

    Source:

  • Sep 28, 2026, 09:56 UTC

    Sunshine Nuohe announced that its wholly owned subsidiary Nuohe Shengtai's STC008 injection met the expected goals in a Phase I clinical trial for treating cancer cachexia in advanced solid tumors.

    Source:

  • Aug 31, 2026, 09:10 UTC

    Sunshine Lake Pharma's first domestic insulin glargine received FDA approval and achieved commercial shipment in the United States, securing overseas orders exceeding 18 million units.

    Source:

  • Aug 25, 2026, 02:30 UTC

    Sunshine Lake Pharma issued a profit warning, expecting a net loss of about 590 million RMB for the first half of 2026, an increase of about 540 million RMB compared to the same period last year.

    Source:

  • Jul 21, 2026, 01:12 UTC

    Sunshine Lake Pharma (06887.HK) repurchased 817,500 shares on the open market on July 20, 2026, for approximately HKD 26.3589 million, to be held as treasury shares.

    Source:

  • Jul 20, 2026, 01:41 UTC

    Sunshine Lake Pharma's self-developed insulin glargine injection received FDA approval for marketing in the United States.

    Source: